Page last updated: 2024-12-08

naltrexonazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

naltrexonazine: binds irreversibly to opiate receptor sites; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID20835606
CHEMBL ID291123
SCHEMBL ID19959700
MeSH IDM0106637

Synonyms (6)

Synonym
nsc 612112
morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, ((5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-ylidene)hydrazone, (5alpha)-
naltrexonazine
CHEMBL291123
SCHEMBL19959700
bdbm50226933
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID149040Inhibition of [3H]DAMPGO binding was determined using standard binding assay in rat brain homogenates against opioid receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
X-ray crystal structure of the opioid ligand naltrexonazine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (42.86)18.7374
1990's2 (28.57)18.2507
2000's1 (14.29)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (14.29%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]